Clinical Trial Detail

NCT ID NCT02668666
Title Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Oana Danciu, MD
Indications

Her2-receptor negative breast cancer

Therapies

Palbociclib + Tamoxifen

Age Groups: adult

Additional content available in CKB BOOST